vTv Therapeutics (Nasdaq: VTVT) granted stock options to two non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The awards cover 23,500 options with a weighted average exercise price of $31.95 per share and a 10-year term.
Each option vests over 4 years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting quarterly over the following 36 months, subject to continued employment and the 2026 Inducement Plan terms. vTv highlights its late-stage pipeline led by cadisegliatin (TTP399), a liver-selective glucokinase activator in a US Phase 3 trial for type 1 diabetes, which has FDA Breakthrough Therapy designation.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The prior inducement-grant event, news_id 1077718, was followed by -2.43% over 24 hours, giving this...
Analysis
The prior inducement-grant event, news_id 1077718, was followed by -2.43% over 24 hours, giving this recurring announcement a relevant historical reference. The effective S-3 shelf remains a financing consideration to monitor.
Key Figures
Stock options granted:23,500 optionsWeighted average exercise price:$31.95 per shareInitial vesting:25%+4 more
"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
breakthrough therapy designationregulatory
"Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
glucokinase activatormedical
"a potential first-in-class oral glucokinase activator being investigated"
A glucokinase activator is a drug that boosts the activity of glucokinase, an enzyme that helps the liver and pancreas sense and lower blood sugar. Think of it as turning up the sensitivity of the body’s sugar thermostat so insulin release and sugar storage respond more effectively; for investors, these drugs matter because they can become new diabetes treatments with sizable market potential while carrying typical development, safety and regulatory risks that affect a company’s value.
adjunctive therapymedical
"a novel, potential first-in-class oral adjunctive therapy to insulin"
Adjunctive therapy is a treatment given in addition to a primary therapy to boost its effectiveness, reduce side effects, or treat related symptoms — like adding a side dish to make a main meal work better. For investors, evidence that an adjunctive therapy improves outcomes, safety, or convenience can expand a product’s use, support stronger regulatory labeling and reimbursement, and increase commercial potential by reaching more patients or strengthening a therapy’s market position.
HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 23,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options that were granted have a weighted average exercise price of $31.95 per share.Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates.The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.
AboutvTvTherapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
What did vTv Therapeutics (VTVT) announce on July 28, 2026 regarding stock options?
vTv Therapeutics announced inducement grants of 23,500 stock options to two non-executive employees under Nasdaq Listing Rule 5635(c)(4). According to vTv Therapeutics, these options were granted as a material inducement to employment and are issued under the company’s 2026 Inducement Plan.
What are the key terms of the vTv Therapeutics (VTVT) inducement stock options?
The inducement options have a weighted average exercise price of $31.95 per share and a 10-year term. According to vTv Therapeutics, each grant vests over four years, with 25% after one year and the remainder vesting quarterly over the following 36 months.
How do the vTv Therapeutics (VTVT) inducement options vest over time?
The inducement options vest over a 4-year schedule. According to vTv Therapeutics, 25% of each grant vests on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting quarterly over the next 36 months, subject to continued employment.
Why were these vTv Therapeutics (VTVT) stock options granted under Nasdaq Listing Rule 5635(c)(4)?
The options were granted as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4). According to vTv Therapeutics, these awards are made outside of shareholder-approved plans but follow the company’s 2026 Inducement Plan and individual stock option agreements.
What is cadisegliatin (TTP399) in vTv Therapeutics’ (VTVT) pipeline and what stage is it in?
Cadisegliatin (TTP399) is a liver-selective glucokinase activator being investigated as an oral adjunctive therapy for type 1 diabetes. According to vTv Therapeutics, it is in a US Phase 3 trial and has received FDA Breakthrough Therapy designation, but safety and efficacy are not yet established.
What diseases is vTv Therapeutics (VTVT) focusing on beyond type 1 diabetes?
vTv Therapeutics is focused on developing oral small-molecule drug candidates for diabetes and other chronic diseases. According to vTv Therapeutics, cadisegliatin leads its clinical pipeline, and the company and its partners are investigating multiple molecules across different chronic indications, though specific additional diseases are not detailed here.
